MOHIT KHERA to Middle Aged
This is a "connection" page, showing publications MOHIT KHERA has written about Middle Aged.
Connection Strength
0.956
-
Testosterone replacement therapy in men on active surveillance for prostate cancer. J Sex Med. 2025 Apr 08; 22(3):432-438.
Score: 0.062
-
Long-Term Satisfaction With Collagenase Clostridium Histolyticum for Peyronie's Disease: Clinical Predictors and Side Effect Profile. Urol Pract. 2025 Jan; 12(1):168-175.
Score: 0.060
-
An Update on Regenerative Medicine Clinical Trials in Erectile Dysfunction: Have We Made Any Progress? Eur Urol Focus. 2019 Jul; 5(4):536-538.
Score: 0.041
-
Penile Prosthesis Implantation in Patients With Peyronie's Disease: Results of the PROPPER Study Demonstrates a Decrease in Patient-Reported Depression. J Sex Med. 2018 05; 15(5):786-788.
Score: 0.038
-
Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism. J Sex Med. 2018 02; 15(2):148-158.
Score: 0.038
-
Clinical Characteristics, Health Care Utilization and Costs Among Men with Primary or Secondary Hypogonadism in a US Commercially Insured Population. J Sex Med. 2017 01; 14(1):88-97.
Score: 0.035
-
Adult-Onset Hypogonadism. Mayo Clin Proc. 2016 07; 91(7):908-26.
Score: 0.034
-
The Evolution of the Inflatable Penile Prosthesis Reservoir and Surgical Placement. J Sex Med. 2015 Nov; 12 Suppl 7:464-7.
Score: 0.032
-
Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer. J Urol. 2015 Nov; 194(5):1271-6.
Score: 0.031
-
Erectile dysfunction as a marker for cardiovascular disease diagnosis and intervention: a cost analysis. J Sex Med. 2015 Apr; 12(4):975-84.
Score: 0.031
-
Depression is correlated with the psychological and physical aspects of sexual dysfunction in men. Int J Impot Res. 2013 Sep; 25(5):194-9.
Score: 0.027
-
12-month observation of testosterone replacement effectiveness in a general population of men. Postgrad Med. 2013 Mar; 125(2):8-18.
Score: 0.027
-
Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013 Aug; 190(2):639-44.
Score: 0.027
-
The 20-year public health impact and direct cost of testosterone deficiency in U.S. men. J Sex Med. 2013 Feb; 10(2):562-9.
Score: 0.026
-
Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013 Jan; 25(1):24-8.
Score: 0.026
-
Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. J Androl. 2012 Sep-Oct; 33(5):927-37.
Score: 0.025
-
Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. 2011 Nov; 8(11):3204-13.
Score: 0.024
-
Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011 Sep; 186(3):1005-11.
Score: 0.024
-
IGF-1 levels are significantly correlated with patient-reported measures of sexual function. Int J Impot Res. 2011 Sep-Oct; 23(5):220-6.
Score: 0.024
-
Testosterone therapy in men with untreated prostate cancer. J Urol. 2011 Apr; 185(4):1256-60.
Score: 0.023
-
The female factor: predicting compliance with a post-prostatectomy erectile preservation program. J Sex Med. 2010 Nov; 7(11):3659-65.
Score: 0.023
-
The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism. Int J Impot Res. 2010 Jan-Feb; 22(1):20-4.
Score: 0.021
-
Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009 Apr; 6(4):1165-1170.
Score: 0.020
-
Can preoperative behavioral training reduce postprostatectomy incontinence? Nat Clin Pract Urol. 2006 Jun; 3(6):302-3.
Score: 0.017
-
Penile constriction devices: a randomized survey study to compare preferences between two medical-grade devices. J Sex Med. 2025 Jan 03; 22(1):43-50.
Score: 0.015
-
Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024 Jan 18; 109(2):569-580.
Score: 0.014
-
Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 12 01; 6(12):e2348692.
Score: 0.014
-
Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023 Jul 13; 389(2):107-117.
Score: 0.014
-
Long-Term Survival Rates of Inflatable Penile Prostheses: Systematic Review and Meta-Analysis. Urology. 2022 08; 166:6-10.
Score: 0.013
-
A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism. Andrology. 2022 05; 10(4):669-676.
Score: 0.012
-
Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J. 2022 03; 245:41-50.
Score: 0.012
-
Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men. J Cardiovasc Pharmacol Ther. 2021 11; 26(6):630-637.
Score: 0.012
-
Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database. Clin Endocrinol (Oxf). 2019 12; 91(6):885-891.
Score: 0.011
-
Caffeine intake is not associated with serum testosterone levels in adult men: cross-sectional findings from the NHANES 1999-2004 and 2011-2012. Aging Male. 2019 Mar; 22(1):45-54.
Score: 0.010
-
Recent advances in the treatment of erectile dysfunction. Postgrad Med J. 2017 Nov; 93(1105):679-685.
Score: 0.009
-
Sexual Rehabilitation After Treatment for Prostate Cancer-Part 1: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2017 Mar; 14(3):285-296.
Score: 0.009
-
Sexual Rehabilitation After Treatment For Prostate Cancer-Part 2: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2017 Mar; 14(3):297-315.
Score: 0.009
-
Diagnosing secondary hypogonadism: important consequences for fertility and reversibility. BJU Int. 2016 Apr; 117(4):552-4.
Score: 0.008
-
The Who, How and What of Real-World Penile Implantation in 2015: The PROPPER Registry Baseline Data. J Urol. 2016 Feb; 195(2):427-33.
Score: 0.008
-
Commentary: Who is a candidate for testosterone therapy? A synthesis of international expert opinions. J Sex Med. 2014 Jul; 11(7):1636-45.
Score: 0.007
-
Measurement of endothelial dysfunction via peripheral arterial tonometry predicts vasculogenic erectile dysfunction. Int J Impot Res. 2014 Nov-Dec; 26(6):218-22.
Score: 0.007
-
Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry. Postgrad Med. 2013 Mar; 125(2):19-29.
Score: 0.007
-
Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS). Clin Interv Aging. 2012; 7:321-30.
Score: 0.006
-
Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS). Pain Med. 2012 May; 13(5):688-98.
Score: 0.006
-
A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(?)) insertion. J Sex Med. 2012 Feb; 9(2):594-601.
Score: 0.006
-
Favorable female sexual function is associated with patient satisfaction after inflatable penile prosthesis implantation. J Sex Med. 2011 Jul; 8(7):1996-2001.
Score: 0.006
-
Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency. Postgrad Med. 2011 May; 123(3):17-27.
Score: 0.006